Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

LaFleur Minerals Inc. operates as a mining company. The Company, through its subsidiaries, engages in the acquisition and exploration of lithium and critical mineral resource properties. LaFleur Minerals serves customers in Canada.

<ul>
<li>LaFleur Minerals Inc. is changing the junior mining paradigm by acquiring both advanced resource-stage and production assets, positioning the Company as a near-term producer in Canada's largest gold-producing region.</li>
<li>LaFleur Minerals is looking to quickly become a gold producer at its Beacon Gold Mill with low-risk assets ready for operation in the Tier 1 mining camp of Val-d'Or, Qu bec, with start-up financing secured.</li>
<li>LaFleur looks to add value to their resource base through confirmation, expansion, and production, thus realizing a multiple of their in-ground value.</li>
</ul>


LaFleur Minerals Inc. is changing the junior mining paradigm by acquiring both advanced resource-stage and production assets, positioning the Company as a near-term producer in Canada's largest gold-producing region.
LaFleur Minerals is looking to quickly become a gold producer at its Beacon Gold Mill with low-risk assets ready for operation in the Tier 1 mining camp of Val-d'Or, Qu bec, with start-up financing secured.
LaFleur looks to add value to their resource base through confirmation, expansion, and production, thus realizing a multiple of their in-ground value.


NetraMark Holdings Inc. operates as a a software technology company. The Company focuses on improving the understanding of how patients, within and across diseases, relate to each other through the integration of multiple types of data via a unique AI enhancing software package. NetraMark Holdings serves customers worldwide.

<ul>
<li>NetraMark recently reiterated its goal to attain C$8m - $10m in contract backlog by mid-2026 &amp; remains focused on forming new contracts, shortening sales cycles and helping sponsors de-risk late-stage trials.</li>
<li>Among the multiple partnerships formed in 2025 expected to contribute to backlog and revenue, NetraMark completed onboarding with global CRO Worldwide Clinical Trial &amp; can now be included in Worldwide's trial bids, an important factor expected to contribute to the contract backlog target.</li>
<li>As AINMF continues to build awareness of its capabilities, last quarter the company announced pending publication of its peer-reviewed scientific study highlighting NetraAI &amp; collaboration with the Centre for Addiction and Mental Health.</li>
</ul>


NetraMark recently reiterated its goal to attain C$8m - $10m in contract backlog by mid-2026 &amp; remains focused on forming new contracts, shortening sales cycles and helping sponsors de-risk late-stage trials.
Among the multiple partnerships formed in 2025 expected to contribute to backlog and revenue, NetraMark completed onboarding with global CRO Worldwide Clinical Trial &amp; can now be included in Worldwide's trial bids, an important factor expected to contribute to the contract backlog target.
As AINMF continues to build awareness of its capabilities, last quarter the company announced pending publication of its peer-reviewed scientific study highlighting NetraAI &amp; collaboration with the Centre for Addiction and Mental Health.


NetraMark Recently Reiterated Its Goal to Attain C$8m

YD Bio Limited operates as a pharmaceutical company. The Company develops nutritional products, health supplements, and therapeutic drugs. YD Bio serves customers worldwide.

<ul><li>Zacks Small-Cap Research Note for Yd Biopharma (YDES)</li></ul>

Zacks Small-Cap Research Note for Yd Biopharma (YDES)

YD Biopharma is an integrated biotechnology company that is poised to have a transformational year as it expands business operations.

Cosmos Health, Inc. operates as a pharmaceutical company. The Company identifies, acquires, develops, and commercializes generic pharmaceuticals, nutraceuticals, OTC medications, and medical devices that improve patients lives and outcomes. Cosmos Health serves patients worldwide.

<ul><li>Cosmos is a vertically integrated healthcare group with a portfolio that spans pharmaceutical and nutraceutical brands, pharmaceutical distribution, proprietary and contract manufacturing as well as an emerging set of technology- and services-oriented assets.</li><li> COSM is a rare opportunity for investors as a company that has solid revenue and expanding its core, while also growing its pharmaceutical business using advanced AI technology.</li></ul>

Cosmos is a vertically integrated healthcare group with a portfolio that spans pharmaceutical and nutraceutical brands, pharmaceutical distribution, proprietary and contract manufacturing as well as an emerging set of technology- and services-oriented assets. COSM is a rare opportunity for investors as a company that has solid revenue and expanding its core, while also growing its pharmaceutical business using advanced AI technology.

COSM:  Initiating Coverage: Increasing Revenue Through Innovation and Efficiency

SeaStar Medical Holding  / Equity Bottom-Up

SeaStar Medical Holding Corporation operates as a holding company. The Company, through its subsidiaries, provides medical devices to prevent respiratory distress syndrome, acute kidney injury, and many other health issues can result in a dangerous cytokine storm. SeaStar Medical Holding serves customers worldwide.

<ul><li>We are initiating coverage of SeaStar Medical Holding Corp. (ICU) with a valuation of $12.00.</li><li>SeaStar is a commercial-stage healthcare company that is developing its first-in-class Selective Cytopheretic Device (SCD) as a means to combat organ failure stemming from a hyperinflammatory immune response and cytokine storm.</li><li>It is applicable for patients suffering from both chronic and acute kidney injury (AKI) as well as other inflammatory diseases.</li></ul>

We are initiating coverage of SeaStar Medical Holding Corp. (ICU) with a valuation of $12.00.SeaStar is a commercial-stage healthcare company that is developing its first-in-class Selective Cytopheretic Device (SCD) as a means to combat organ failure stemming from a hyperinflammatory immune response and cytokine storm.It is applicable for patients suffering from both chronic and acute kidney injury (AKI) as well as other inflammatory diseases.

SeaStar Medical Holding Corp - January 13, 2026